Sonia Davis, DrPH
Dr. Davis is a biostatistician with expertise in the design, planning, and implementation of clinical trials. She also has experience with data and safety monitoring boards, analysis methods for clinical trials with missing data, and multiple comparison strategies. Her career has spanned academia and industry, including 17 years leading clinical trials for a pharmaceutical company.
- Director, Collaborative Studies Coordinating Center, University of North Carolina at Chapel Hill
- Professor of the Practice, Department of Biostatistics, University of North Carolina at Chapel Hill
- DrPH, 1994, University of North Carolina at Chapel Hill
- Davis S. M., Stroup T. S., Koch G. G., Davis C. E., Rosenheck R. A., and Lieberman J. A. (2011). Time to all-cause treatment discontinuation as the primary outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, Statistics in Biopharmaceutical Research, 3(2), 253-265.
- Lieberman J. A., Stroup T. S., McEvoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O., Keefe R. S. E., Davis S. M., Davis C. E., Lebowitz B. D., Severe J., and Hsiao J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, New England Journal of Medicine, 353(12), 1209-1223.
- Schneider L. S., Tariot P. N., Dagerman K. S., Davis S., Hsiao J. K., Ismail M. S., Lebowitz B. D., Constantine J., Lyketsos G., Ryan M., Stroup T. S., Sultzer D. L., Weintraub D., and Lieberman J A. (2006). Effectiveness of atypical antipsychotic drugs for patients with alzheimer’s disease. New England Journal of Medicine, 355(15), 1525-1537.
- Rush A. J., Marangell L. B., Sackeim H. A., George M. S., Brannan S. K., Davis S. M., Howland R., Kling M. A., Rittberg B. R., Burke W. J., Rappaport M. H., Zajecka J., Nierenberg A. A., Husain M. M., Ginsberg D., and Cooke R. G. (2005). Vagus nerve stimulation for treatment-resistant depression: A randomized, controlled acute phase trial. Biological Psychiatry, 58(5), 347-354.
- Davis S. M., Koch G. G., Davis C. E., and LaVange L. M. (2003). Statistical approaches to effectiveness measurement and outcome-driven re-randomization in the CATIE studies. Schizophrenia Bulletin, 29(1), 73-80.
- A Statistician's Role in Interim Analysis
- Be the First to Know
- Biostatistics Core at NC TraCS
- Challenges of Using Medical Records for Comparative Effectiveness Studies
- How to Speak With a Biostatistician
- Include a Statistician from the Beginning
- Rapidly Changing Statistical Methods
- Research Design Considerations for Comparative Effectiveness Studies
- Serving Industry and Academia